Li Yujun, Wu Tong, Saeed Muhammad Muddasar, Cui Xiaonan
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Front Oncol. 2024 Nov 18;14:1416349. doi: 10.3389/fonc.2024.1416349. eCollection 2024.
Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent incorporated into metastatic colorectal cancer treatment strategies and demonstrated broad-spectrum anti-tumor efficacy. Commonly reported adverse events include hypertension, proteinuria, gastrointestinal perforation, bleeding, and thromboembolism. However, there are only a few reports on abdominal aortic aneurysms (AAA) as a complication of bevacizumab therapy. Given the high risk of fatal rupture with AAA, we present a case of bevacizumab-associated AAA to raise clinician awareness of this possible, rare, and serious adverse reaction.
贝伐单抗是一种靶向血管内皮生长因子（VEGF）的人源化单克隆抗体，是首个被纳入转移性结直肠癌治疗策略的抗血管生成药物，并显示出广谱抗肿瘤疗效。常见的不良事件包括高血压、蛋白尿、胃肠道穿孔、出血和血栓栓塞。然而，关于贝伐单抗治疗并发症导致腹主动脉瘤（AAA）的报道仅有少数几例。鉴于AAA有致命破裂的高风险，我们报告一例与贝伐单抗相关的AAA病例，以提高临床医生对这种可能发生的、罕见且严重的不良反应的认识。
